Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment

Nerve cells in the substantia nigra pars compacta (SNPC) are known to express tyrosine hydroxylase (TH). By means of light and electron microscopical immunohistochemical techniques, we have shown that the dopaminergic neurons of SNPC express also kynurenine aminotransferase (KAT-I), the enzyme takin...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Knyihár-Csillik Erzsébet
Csillik Bertalan
Pákáski Magdolna
Krisztinné Péva Beáta
Dobó Endre
Okuno E.
Vécsei László
Dokumentumtípus: Cikk
Megjelent: 2004
Sorozat:NEUROSCIENCE 126 No. 4
doi:10.1016/j.neuroscience.2004.04.043

mtmt:1032209
Online Access:http://publicatio.bibl.u-szeged.hu/10116
LEADER 02552nab a2200277 i 4500
001 publ10116
005 20190508170016.0
008 161220s2004 hu o 0|| zxx d
022 |a 0306-4522 
024 7 |a 10.1016/j.neuroscience.2004.04.043  |2 doi 
024 7 |a 1032209  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a zxx 
100 2 |a Knyihár-Csillik Erzsébet 
245 1 0 |a Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment  |h [elektronikus dokumentum] /  |c  Knyihár-Csillik Erzsébet 
260 |c 2004 
300 |a 899-914 
490 0 |a NEUROSCIENCE  |v 126 No. 4 
520 3 |a Nerve cells in the substantia nigra pars compacta (SNPC) are known to express tyrosine hydroxylase (TH). By means of light and electron microscopical immunohistochemical techniques, we have shown that the dopaminergic neurons of SNPC express also kynurenine aminotransferase (KAT-I), the enzyme taking part in the formation of kynurenic acid, a neuroprotectant which is one of the endogeneous antagonists of N-methyl-D-aspartate receptors. It was also found that microglial cells and astrocytes express KAT-I. It has been shown that the highly selective dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), widely used as a model of Parkinson's disease (PD), affects not only TH of dopaminergic neurons in the SNPC but also their KAT-I immunoreactivity as well: MPTP treatment decreased the number and optical density of KAT-I immunoreactive SNPC neurons. Decrease of KAT-I after MPTP treatment has been proved also by Western blot analysis. MPTP also reduced KAT-I immunoreactivity of microglial cells, except for those involved in reactive gliosis, which were arranged in groups surrounding affected neurons of the SNPC; also the number of KAT-I immunoreactive (IR) astroglial cells was increased in SNPC. We conclude that MPTP treatment may have a dual effect: in addition to being deleterious for neurons expressing TH and KAT-I, it also affects glial cells which could exacerbate the neurodegenerative process characterizing PD. (C) 2004 IBRO. Published by Elsevier Ltd. All rights reserved. 
700 0 1 |a Csillik Bertalan  |e aut 
700 0 1 |a Pákáski Magdolna  |e aut 
700 0 2 |a Krisztinné Péva Beáta  |e aut 
700 0 2 |a Dobó Endre  |e aut 
700 0 2 |a Okuno E.  |e aut 
700 0 2 |a Vécsei László  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/10116/1/Knyihar_E._Decrease_KAT_1_u.pdf  |z Dokumentum-elérés